Which peptides are studied in relation to sex hormone-binding globulin?

Sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein, also referred to in the literature as sex steroid-binding globulin (SSBG) or testosterone-estradiol-binding globulin (TeBG). It is classified as a steroid-binding transport protein of hepatic origin, and its circulating concentration is the readout most often used when researchers ask whether a compound alters the androgen-to-estrogen ratio available to target tissues. The evidence block supplied for this page does not provide a sequence, molecular formula, or molecular weight for SHBG, and none is asserted here.

The pathway that dominates this literature is the insulin-sensitivity axis: hyperinsulinaemia is described as enhancing ovarian androgen production while reducing hepatic SHBG synthesis, which in turn aggravates hyperandrogenism and reproductive abnormalities [1]. Work in this area therefore centres on compounds that act on incretin signalling and glucose homeostasis rather than on SHBG itself.

Research Studies

Vildagliptin and hepatic SHBG synthesis in polycystic ovary syndrome

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibition enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis [1]. Because hyperinsulinaemia is reported to reduce hepatic SHBG synthesis, a compound that lowers insulin exposure is a plausible upstream modifier of SHBG concentration in this population [1].

The population in which this has been framed is patients with polycystic ovary syndrome (PCOS), described as a common endocrine and metabolic disorder characterised by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, with insulin resistance playing a central role in its pathophysiology [1].

Vildagliptin versus metformin and androgen excess in PCOS

A registered comparison of vildagliptin against metformin in patients with PCOS places the two agents in the same study frame [1]. Emerging evidence cited in that record suggests DPP-4 inhibition may also influence body weight, androgen excess, and inflammation [1]. The record does not report SHBG as a measured outcome in the material supplied, so any link between the two agents and SHBG concentration in this comparison remains inferential rather than demonstrated.

Incretin-axis compounds and the insulin–SHBG relationship

The mechanistic case for studying incretin-acting compounds against SHBG rests on a single described step: hyperinsulinaemia reduces hepatic SHBG synthesis [1]. Compounds that act on the incretin axis are therefore studied as indirect modulators of that step rather than as direct SHBG binders or SHBG secretagogues [1].

DPP-4 inhibition and inflammation in PCOS

Inflammation is listed among the domains that DPP-4 inhibition may influence in the PCOS context [1]. Because SHBG is a hepatic protein and inflammatory signalling is a recognised input to hepatic protein synthesis, this line of work is sometimes grouped with the insulin-sensitivity work, but the supplied evidence does not establish an SHBG-specific effect [1].

DPP-4 inhibition and body weight in PCOS

Body weight is also named as a domain of emerging interest for DPP-4 inhibition [1]. Adiposity is a determinant of circulating SHBG in the general endocrine literature, and the PCOS studies described here enrol participants on the basis of metabolic phenotype, which is why weight-related endpoints and SHBG are frequently discussed together [1].

SHBG and hepatic steatosis in adolescent girls with PCOS

A separate prospective, observational, cross-sectional mechanistic pilot study evaluates whether PCOS contributes to hepatic steatosis in adolescent girls independently of adiposity [2]. The study enrols 150 girls aged 10–18 years into three groups of 50: girls with PCOS and obesity, age- and body mass index-matched girls with obesity but without PCOS, and healthy normal-weight girls [2].

Each participant undergoes a single evaluation comprising anthropometry, clinical and biochemical phenotyping, transient elastography with controlled attenuation parameter, two-dimensional shear wave elastography, and a single venous blood sample [2]. This design is relevant to SHBG research because it isolates the hepatic compartment — the site of SHBG synthesis — from adiposity as a confounder, and because biochemical phenotyping of a single venous sample is the format in which SHBG is typically measured [2].

Hepatic steatosis as a model for SHBG synthesis capacity

Because SHBG is produced in the liver, a study that quantifies hepatic fat and stiffness in the same participants who provide a venous sample offers a model in which hepatic synthetic capacity and SHBG concentration can be examined together [2]. The supplied evidence does not report SHBG values from this study, and no such values are stated here.

Where the evidence is indirect or non-human

Every item in the supplied evidence concerns human participants: patients with PCOS in the vildagliptin comparison [1] and adolescent girls aged 10–18 years in the steatosis study [2]. No animal-only or in vitro data on SHBG and these compounds is provided in the evidence block, and none is claimed. The mechanistic statements linking insulin to hepatic SHBG synthesis are described as background pathophysiology rather than as results of a completed SHBG endpoint [1].

If you are reading this for personal health reasons

The materials described on this page are supplied for laboratory research use only, and we do not provide dosing information or medical guidance of any kind. Nothing here is a recommendation to use any compound, and no outcome is promised or implied. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome — ClinicalTrials.gov
• [2] Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) — ClinicalTrials.gov